TY - JOUR
T1 - Food Allergy in Adults
T2 - Substantial Variation in Prevalence and Causative Foods Across Europe
AU - Lyons, Sarah A.
AU - Burney, Peter G.J.
AU - Ballmer-Weber, Barbara K.
AU - Fernandez-Rivas, Montserrat
AU - Barreales, L.
AU - Clausen, Michael
AU - Dubakiene, Ruta
AU - Fernandez-Perez, Cristina
AU - Fritsche, Philipp
AU - Jedrzejczak-Czechowicz, Monika
AU - Kowalski, Marek L.
AU - Kralimarkova, T.
AU - Kummeling, I.
AU - Mustakov, Tihomir B.
AU - Lebens, Ans F.M.
AU - van Os-Medendorp, Harmieke
AU - Papadopoulos, Nikolaos G.
AU - Popov, Todor A.
AU - Sakellariou, Alexandros
AU - Welsing, Paco M.J.
AU - Potts, J.
AU - Mills, E. N.Clare
AU - van Ree, Ronald
AU - Knulst, André C.
AU - Le, Thuy My
N1 - Funding Information:
Conflicts of interest: All authors declare a grant from the European Union through EuroPrevall (grant no. FP6-FOOD-CT-2005-514000) during the conduct of the study. Outside submitted work: B. K. Ballmer-Weber reports personal fees from ThermoFisher Scientific. M. Fernandez-Rivas reports grants from the European Commission and the Spanish government (MINECO, ISCIII); a patent PCT/ES2014/070634 issued; grants and personal fees from Aimmune Therapeutics ; and personal fees from Allergy Therapeutics, Fundacion SEACI, HAL Allergy B.V., ThermoFisher Scientific, Schreiber Foods, and DBV. E. N. C. Mills reports grants from Reacta Biotech ; is Chief Scientific Advisor and shareholder of Reacta Biotech Ltd, a start-up developed to commercialize foods for use in oral food challenges; and has 2 patents, PCT/GB2016/051637 and PCT/GB2016/053829, pending to Reacta Biotech Ltd. N. G. Papadopoulos reports grants from Gerolymatos and personal fees from HAL Allergy B.V., Novartis Pharma AG, Menarini, and Mylan. R. Van Ree reports personal fees from ThermoFisher Scientific. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
This work was funded by the European Union through EuroPrevall (grant no. FP6-FOOD-CT-2005-514000).Conflicts of interest: All authors declare a grant from the European Union through EuroPrevall (grant no. FP6-FOOD-CT-2005-514000) during the conduct of the study. Outside submitted work: B. K. Ballmer-Weber reports personal fees from ThermoFisher Scientific. M. Fernandez-Rivas reports grants from the European Commission and the Spanish government (MINECO, ISCIII); a patent PCT/ES2014/070634 issued; grants and personal fees from Aimmune Therapeutics; and personal fees from Allergy Therapeutics, Fundacion SEACI, HAL Allergy B.V., ThermoFisher Scientific, Schreiber Foods, and DBV. E. N. C. Mills reports grants from Reacta Biotech; is Chief Scientific Advisor and shareholder of Reacta Biotech Ltd, a start-up developed to commercialize foods for use in oral food challenges; and has 2 patents, PCT/GB2016/051637 and PCT/GB2016/053829, pending to Reacta Biotech Ltd. N. G. Papadopoulos reports grants from Gerolymatos and personal fees from HAL Allergy B.V., Novartis Pharma AG, Menarini, and Mylan. R. Van Ree reports personal fees from ThermoFisher Scientific. The rest of the authors declare that they have no relevant conflicts of interest. This work was funded by the European Union through EuroPrevall (grant no. FP6-FOOD-CT-2005-514000). Conflicts of interest: All authors declare a grant from the European Union through EuroPrevall (grant no. FP6-FOOD-CT-2005-514000) during the conduct of the study. Outside submitted work: B. K. Ballmer-Weber reports personal fees from ThermoFisher Scientific. M. Fernandez-Rivas reports grants from the European Commission and the Spanish government (MINECO, ISCIII); a patent PCT/ES2014/070634 issued; grants and personal fees from Aimmune Therapeutics; and personal fees from Allergy Therapeutics, Fundacion SEACI, HAL Allergy B.V., ThermoFisher Scientific, Schreiber Foods, and DBV. E. N. C. Mills reports grants from Reacta Biotech; is Chief Scientific Advisor and shareholder of Reacta Biotech Ltd, a start-up developed to commercialize foods for use in oral food challenges; and has 2 patents, PCT/GB2016/051637 and PCT/GB2016/053829, pending to Reacta Biotech Ltd. N. G. Papadopoulos reports grants from Gerolymatos and personal fees from HAL Allergy B.V., Novartis Pharma AG, Menarini, and Mylan. R. Van Ree reports personal fees from ThermoFisher Scientific. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
This work was funded by the European Union through EuroPrevall (grant no. FP6-FOOD-CT-2005-514000 ).
Publisher Copyright:
© 2019 American Academy of Allergy, Asthma & Immunology
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Background: According to the community-based EuroPrevall surveys, prevalence of self-reported food allergy (FA) in adults across Europe ranges from 2% to 37% for any food and 1% to 19% for 24 selected foods. Objective: To determine the prevalence of probable FA (symptoms plus specific IgE-sensitization) and challenge-confirmed FA in European adults, along with symptoms and causative foods. Methods: In phase I of the EuroPrevall project, a screening questionnaire was sent to a random sample of the general adult population in 8 European centers. Phase II consisted of an extensive questionnaire on reactions to 24 preselected commonly implicated foods, and measurement of specific IgE levels. Multiple imputation was performed to estimate missing symptom and serology information for nonresponders. In the final phase, subjects with probable FA were invited for double-blind placebo-controlled food challenge. Results: Prevalence of probable FA in adults in Athens, Reykjavik, Utrecht, Lodz, Madrid, and Zurich was respectively 0.3%, 1.4%, 2.1%, 2.8%, 3.3%, and 5.6%. Oral allergy symptoms were reported most frequently (81.6%), followed by skin symptoms (38.2%) and rhinoconjunctivitis (29.5%). Hazelnut, peach, and apple were the most common causative foods in Lodz, Utrecht, and Zurich. Peach was also among the top 3 causative foods in Athens and Madrid. Shrimp and fish allergies were relatively common in Madrid and Reykjavik. Of the 55 food challenges performed, 72.8% were classified as positive. Conclusions: FA shows substantial geographical variation in prevalence and causative foods across Europe. Although probable FA is less common than self-reported FA, prevalence still reaches almost 6% in parts of Europe.
AB - Background: According to the community-based EuroPrevall surveys, prevalence of self-reported food allergy (FA) in adults across Europe ranges from 2% to 37% for any food and 1% to 19% for 24 selected foods. Objective: To determine the prevalence of probable FA (symptoms plus specific IgE-sensitization) and challenge-confirmed FA in European adults, along with symptoms and causative foods. Methods: In phase I of the EuroPrevall project, a screening questionnaire was sent to a random sample of the general adult population in 8 European centers. Phase II consisted of an extensive questionnaire on reactions to 24 preselected commonly implicated foods, and measurement of specific IgE levels. Multiple imputation was performed to estimate missing symptom and serology information for nonresponders. In the final phase, subjects with probable FA were invited for double-blind placebo-controlled food challenge. Results: Prevalence of probable FA in adults in Athens, Reykjavik, Utrecht, Lodz, Madrid, and Zurich was respectively 0.3%, 1.4%, 2.1%, 2.8%, 3.3%, and 5.6%. Oral allergy symptoms were reported most frequently (81.6%), followed by skin symptoms (38.2%) and rhinoconjunctivitis (29.5%). Hazelnut, peach, and apple were the most common causative foods in Lodz, Utrecht, and Zurich. Peach was also among the top 3 causative foods in Athens and Madrid. Shrimp and fish allergies were relatively common in Madrid and Reykjavik. Of the 55 food challenges performed, 72.8% were classified as positive. Conclusions: FA shows substantial geographical variation in prevalence and causative foods across Europe. Although probable FA is less common than self-reported FA, prevalence still reaches almost 6% in parts of Europe.
KW - Adults
KW - Causative foods
KW - Europe
KW - Food allergy
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=85065026408&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2019.02.044
DO - 10.1016/j.jaip.2019.02.044
M3 - Article
C2 - 30898689
AN - SCOPUS:85065026408
SN - 2213-2198
VL - 7
SP - 1920-1928.e11
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 6
ER -